Dyadic International Launches Public Stock Offering, Shares Plummet 11.5%
ByAinvest
Thursday, Jul 31, 2025 12:23 am ET1min read
DYAI--
The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including product development, sales, and marketing. The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273829) initially filed with the Securities and Exchange Commission (SEC) on August 9, 2023 and declared effective by the SEC on August 25, 2023 [1].
Dyadic's stock fell 11.5% post-market on Wednesday following the announcement, reflecting investor sentiment towards the potential dilution of existing shareholders [2]. The offering signals Dyadic's need for additional funding to support its ongoing operations and growth strategies in its biotechnology business focused on precision engineered functional input proteins.
The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. Investors can obtain electronic copies of the preliminary prospectus supplement and the accompanying prospectus by visiting the SEC’s website at www.sec.gov or by contacting Craig-Hallum Capital Group LLC.
References:
[1] https://finance.yahoo.com/news/dyadic-international-inc-announces-proposed-200200313.html
[2] https://www.stocktitan.net/news/DYAI/dyadic-international-inc-announces-proposed-public-offering-of-nhvmepesqarj.html
JUNS--
Dyadic International has initiated a public stock offering to raise funds for working capital, product development, and sales and marketing efforts. Proceeds from the offering will be used to support the company's growth and expansion. DYAI shares fell 11.5% post-market on Wednesday following the announcement.
Jupiter, Fla., July 30, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins, has announced the commencement of an underwritten public offering of shares of common stock. The offering is subject to market and other conditions and is being managed by Craig-Hallum Capital Group LLC as the sole underwriter.The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including product development, sales, and marketing. The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273829) initially filed with the Securities and Exchange Commission (SEC) on August 9, 2023 and declared effective by the SEC on August 25, 2023 [1].
Dyadic's stock fell 11.5% post-market on Wednesday following the announcement, reflecting investor sentiment towards the potential dilution of existing shareholders [2]. The offering signals Dyadic's need for additional funding to support its ongoing operations and growth strategies in its biotechnology business focused on precision engineered functional input proteins.
The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. Investors can obtain electronic copies of the preliminary prospectus supplement and the accompanying prospectus by visiting the SEC’s website at www.sec.gov or by contacting Craig-Hallum Capital Group LLC.
References:
[1] https://finance.yahoo.com/news/dyadic-international-inc-announces-proposed-200200313.html
[2] https://www.stocktitan.net/news/DYAI/dyadic-international-inc-announces-proposed-public-offering-of-nhvmepesqarj.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet